These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 16925499)

  • 1. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.
    Müller T; Russ H
    Expert Opin Pharmacother; 2006 Sep; 7(13):1715-30. PubMed ID: 16925499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy].
    Ellrichmann G; Russ H; Müller T
    Fortschr Neurol Psychiatr; 2007 Jul; 75(7):387-96. PubMed ID: 17443441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.
    Antonini A; Chaudhuri KR; Martinez-Martin P; Odin P
    CNS Drugs; 2010 Feb; 24(2):119-29. PubMed ID: 20088619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
    Di Luca DG; Reyes NGD; Fox SH
    Drugs; 2022 Jul; 82(10):1027-1053. PubMed ID: 35841520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update.
    Leta V; Jenner P; Chaudhuri KR; Antonini A
    Expert Opin Drug Saf; 2019 Dec; 18(12):1203-1218. PubMed ID: 31619083
    [No Abstract]   [Full Text] [Related]  

  • 10. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.
    Kostic V; Przedborski S; Flaster E; Sternic N
    Neurology; 1991 Feb; 41(2 ( Pt 1)):202-5. PubMed ID: 1992362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Cedarbaum JM
    Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
    Bachmann CG; Zapf A; Brunner E; Trenkwalder C
    Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
    Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Verhagen Metman L
    Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.